数据来源:AD协会-《2023 Alzheimer`s disease facts and figures》,Ronald C. Petersen et.al《How early can we diagnose Alzheimer disease (and is it sufficient)?》,华创证券 注:CSF:脑脊液,PET:正电子发射断层扫描 诊断技术的进步使得AD...
This article describes the public health impact of Alzheimer\'s disease, including prevalence and incidence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society. The Special Report examines the patient journey from awareness ...
Cross-sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middle-aged individuals with a parental history of either autosomal dominant or late-onset Alzheimer’s disease. Alzheimers Dement. 19, 2923–2932 (2023). Article CAS PubMed Google Scholar Yang, Y. et al. ...
Alzheimer’s disease is a progressive neurological illness that impairs thinking and the independence of millions of people worldwide. Today more than 55M people have dementia worldwide, with 60-70% of cases being Alzheimer’s disease.
1. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 2023;19(4):1598-1695. doi:10.1002/alz.13016 2. 2. Zampatti S, Ragazzo M, Peconi C, et al. Genetic Counselling Improves the Molecular Characterisation of Dementing Disorders. J Pers Med. 2021;11(6):...
2023 Alzheimer's disease facts and figures 2023 Alzheimer’s Disease Drug Development Pipeline Who Funds Alzheimer’s Disease Drug Development? Virtual Issue:World Wide FINGERS Publications Special Topic Issue: Psychosocial Measures Special Topic Section: Alzheimer's Disease Among Adults with Down Syndrome...
This report provides information to increase understanding of the public health impact of Alzheimer's disease (AD). Topics addressed include incidence, prevalence, mortality rates, health expenditures and costs of care, and effect on caregivers and society. The report also explores issues that arise ...
In this review article we examine the various types of diagnostic biomarkers which are used in the early detection of Alzheimer’s disease. This review summerizes the A/T/N classification system for Alzheimer’s biomarkers and its use in the biomarker-based diagnosis of Alzheimer’s disease. Fur...
Neuropsychiatric symptoms due to Alzheimer’s disease (AD) and mild cognitive impairment (MCI) can decrease quality of life for patients and increase caregiver burden. Better characterization of neuropsychiatric symptoms and methods of analysis are neede
题主这个问题很是应景。2014年新版的Alzheimer’s Disease Facts and Figures中,特别有一个栏目Special ...